EcoDrugPlus

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSSLDG00000000064
Gene Symbol: LOC111650434
3 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Gamma-Like

Ensembl ID : ENSSLDG00000015904
Gene Symbol: LOC111658805
3 Cross references
349 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Gamma-Like

Ensembl ID : ENSSLDG00000007100
Gene Symbol: LOC111667647
3 Cross references
349 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSSLDG00000012135
Gene Symbol: LOC111651451
2 Cross references
53 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSSLDG00000021025
Gene Symbol: LOC111671089
3 Cross references
189 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSSLDG00000006382
Gene Symbol: LOC111649932
2 Cross references
191 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSSLDG00000018558
Gene Symbol: PIK3CA
3 Cross references
177 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSSLDG00000015103
Gene Symbol: PIK3CA
4 Cross references
208 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSSLDG00000024911
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSSLDG00000001013
Gene Symbol: PIK3CD
3 Cross references
211 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSSLDG00000017243
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSSLDG00000023103
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).